Drug Trial Radar · NCT01208389
Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2
Last checked: Nov 20, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Nov 2010
Primary completion
Oct 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- Spark Therapeutics, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Sep 24, 2010
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 8 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a follow-on to a Phase 1 dose-escalation and safety study.
Conditions
- Leber Congenital Amaurosis
Interventions
voretigene neparvovec-rzylBiological
One time, subretinal administration of 1.5E11 vg AAV2-hRPE65v2 vector in 300 microliters to the contralateral, previously uninjected eye.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events as a measure of safety and tolerabilityTime frame: 15 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.